SHINSUKE MIZOGUCHI
Papers
1
Total Citations
5
H-Index
1
About
Shinsuke Mizoguchi is a leading urologic oncologist whose research focuses on advanced renal cell carcinoma (RCC), particularly cases involving inferior vena cava (IVC) tumor thrombus—a complex and high-risk condition. His most notable contribution is pioneering the use of preoperative combination therapy with lenvatinib and pembrolizumab for RCC with IVC thrombus, as detailed in his 2024 landmark paper. This work demonstrated that this immunotherapy-tyrosine kinase inhibitor combination is not only safe but effective in reducing tumor thrombus burden prior to surgery, potentially transforming management of this challenging disease. With 5 citations already, this study is gaining rapid attention for addressing a critical gap in treatment protocols. Mizoguchi’s research bridges surgical oncology and systemic therapy, offering new hope for patients with advanced RCC. His work underscores a shift toward neoadjuvant immunotherapy combinations, positioning him as an emerging authority in urologic oncology. For students and researchers, Mizoguchi exemplifies how targeted, innovative approaches can tackle even the most formidable oncologic challenges.
Research Focus
Key Achievements
Top Papers
- 1